http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jeong, Lak Shin,Shantanu Pal,Choe, Seung Ah,Choi, Won Jun,Kenneth A. Jacobson,Zhan-Guo Gao,Athena M. Klutz,Xiyan Hou,Kim, Hea Ok,Lee, Hyuk Woo,Lee, Sang Kook,Dilip K. Tosh,Moon, Hyung Ryong 이화여자대학교 약학연구소 2009 藥學硏究論文集 Vol.- No.19
Novel D- and L-4´-thioadenosine derivatives lacking the 4´-hydroxymethyl moiety were synthesized, starting from D-mannose and D-gulonic γ-lactone, respectively, as potent and selective species-independent A₃ adenosine receptor (AR) antagonists. Among the novel 4´-truncated 2-H nucleosides tested, a N^(6)-(3-chlorobenzyl) derivative 7c was the most potent at the human A₃ AR (K_(i) = 1.5 nM), but a N^(6)-(3-bromobenzyl) derivative 7d showed the optimal species-independent binding affinity.
Jeong, Seung-Yong,Park, Ji Won,Nam, Byung Ho,Kim, Sohee,Kang, Sung-Bum,Lim, Seok-Byung,Choi, Hyo Seong,Kim, Duck-Woo,Chang, Hee Jin,Kim, Dae Yong,Jung, Kyung Hae,Kim, Tae-You,Kang, Gyeong Hoon,Chie, E Elsevier 2014 LANCET ONCOLOGY Vol.15 No.7
<P><B>Summary</B></P> <P><B>Background</B></P> <P>Compared with open resection, laparoscopic resection of rectal cancers is associated with improved short-term outcomes, but high-level evidence showing similar long-term outcomes is scarce. We aimed to compare survival outcomes of laparoscopic surgery with open surgery for patients with mid-rectal or low-rectal cancer.</P> <P><B>Methods</B></P> <P>The Comparison of Open versus laparoscopic surgery for mid or low REctal cancer After Neoadjuvant chemoradiotherapy (COREAN) trial was an open-label, non-inferiority, randomised controlled trial done between April 4, 2006, and Aug 26, 2009, at three centres in Korea. Patients (aged 18–80 years) with cT3N0–2M0 mid-rectal or low-rectal cancer who had received preoperative chemoradiotherapy were randomly assigned (1:1) to receive either open or laparoscopic surgery. Randomisation was stratified by sex and preoperative chemotherapy regimen. Investigators were masked to the randomisation sequence; patients and clinicians were not masked to the treatment assignments. The primary endpoint was 3 year disease-free survival, with a non-inferiority margin of 15%. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00470951.</P> <P><B>Findings</B></P> <P>We randomly assigned 340 patients to receive either open surgery (n=170) or laparoscopic surgery (n=170). 3 year disease-free survival was 72·5% (95% CI 65·0–78·6) for the open surgery group and 79·2% (72·3–84·6) for the laparoscopic surgery group, with a difference that was lower than the prespecified non-inferiority margin (–6·7%, 95% CI −15·8 to 2·4; p<0·0001). 25 (15%) patients died in the open group and 20 (12%) died in the laparoscopic group. No deaths were treatment related.</P> <P><B>Interpretation</B></P> <P>Our results show that laparoscopic resection for locally advanced rectal cancer after preoperative chemoradiotherapy provides similar outcomes for disease-free survival as open resection, thus justifying its use.</P> <P><B>Funding</B></P> <P>National Cancer Center, South Korea.</P>
Role of reactive thrombocytosis after primary cytoreductive surgery in advanced ovarian cancer
( Seung Hun Baek ),( Joseph J. Noh ),( Jung In Shim ),( Jun Hyeok Kang ),( Soo Young Jeong ),( Chel Hun Choi ),( Tae-joong Kim ),( Jeong-won Lee ),( Byoung-gie Kim ),( Duk-soo Bae ),( Yoo-young Lee ) 대한산부인과학회 2020 대한산부인과학회 학술대회 Vol.106 No.-
Objective: Surgery induced thrombocytosis occurs frequently in various disease. We investigated the incidence of reactive thrombocytosis after maximal cytoreductive surgery in epithelial ovarian cancer and its role on survival. Methods: An electronic chart review was performed of advanced epithelial ovarian cancer patients who had primary cytoreductive surgery from January 1, 2012, and December 31, 2017. Besides from known clinical prognostic factors, serum platelet counts at various time points including before surgery, during peri-operative period, and on each cycle of adjuvant chemotherapy were collected. Results: 474 patients were eligible for the analysis. Median age was 55 years (18 -88) and pretreatment CA 125 was 1519.2 U/mL (5.5-16719). 401 patients (84.6%) were FIGO Stage III and serous histology was most common (405 patients, 85.4%). 79 patients (22.6%) had splenectomy and optimal cytoreduction (residual < 1cm) was achieved at 326 patients (68.8%). Thrombocytosis was observed in 273 patients (57.6%) patients in the entire cohort. Especially, higher platelet counts were observed in patients with splenectomy compared without splenectomy (e.g. on post-operative day 12, p<0.001). Subgroup of patients who still had thrombocytosis during adjuvant chemotherapy showed poorer survivals than the others. In particular, thrombocytosis on 5th cycle of adjuvant chemotherapy showed most significant impact on overall survival (HR; 1.871, 95%CI; 1.034-3.386, p=0.038) among various time points in multivariate analysis. In a logistic regression model, splenectomy (p<0.001) and optimal cytoreduction (p=0.025) significantly attributed to thrombocytosis on 5th cycle. Conclusion: Our findings suggest that reactive thrombocytosis after primary cytoreductive surgery is associated with poor survival in advanced ovarian cancer, particularly when splenectomy was performed and thrombocytosis was observed during adjuvant chemotherapy. New approaches to increase oncological outcomes are needed for this subgroup of patients.
The Effect of Human Placental Extract on Rheumatoid Arthritis in an Animal Model
Jeong Dong Park,신희석,Sang-Il Lee,A Ram Kim,Jong Moon Park,Sang-Yeop Shin,Jun Hwa Shin,Seung Won Moon,Hyun Park,오민균 대한재활의학회 2012 Annals of Rehabilitation Medicine Vol.36 No.2
Objective To assess the effi cacy of human placental extract (HPE) in an animal model of rheumatoid arthritis (RA). Method We used (i) KRN C57BL/6 TCR transgenic x NOD mice (KBx/N) serum transfer arthritis and (ii) collageninduced arthritis (CIA) mice to evaluate the effi cacy of HPE (1 ul or 100 ul, intra-peritoneal, three times per week)on RA. Incidence, severity of arthritis, and hind-paw thickness were quantifi ed. Joint destruction was analyzed using modifi ed mammographic imaging. Histopathological analysis for infl ammation, cartilage, and osteoclasts was performed using Hematoxylin-eosin (H-E), safranin-O, and tartrate-resistant acidic phosphatase (TRAP). ELISAs were used for detection of various cytokines in serum and joint tissue. Results Th ere were no signifi cant diff erences in incidence of arthritis, clinical scores of arthritis, and hind-paw thickness between HPE-treated and vehicle-treated groups for up to 2 weeks in the KBx/N serum transfer arthritis model. Histopathological analysis also showed no diff erences 2 weeks after treatment. Levels of TNF-α, IL-1β, IL-6, IL-10, and RANKL in serum and joint tissues were similar in all groups. Furthermore, there were no diff erences in clinical, radiological, and histological parameters between HPE-treated and vehicle-treated group for 3 weeks in the CIA model. Conclusion Systemic treatment with HPE has no benefi cial eff ects on arthritis in animal models of RA. Th erefore,indiscreet use of HPE in RA should be forbidden.
The expression of TLRs in pulmonary neuron in bleomycin induced pulmonary fibrosis model
( Won Jai Jung ),( Sue In Choi ),( Eun Joo Lee ),( Kyung Hoon Min ),( Gyu Young Hur ),( Seung Heon Lee ),( Sung Yong Lee ),( Je Hyeong Kim ),( Chol Shin ),( Jae Jeong Shim ),( Kwang Ho In ),( Kyung Ho 대한결핵 및 호흡기학회 2015 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.120 No.-
Background: The family of Toll-like receptors (TLRs) plays a key role in controlling innate immune responses to a wide variety of pathogen-associated molecules. Nerve cells originated from lung are considered to be related with clinical respiratory symptoms including coughing, dyspnea. However, investigation of TLRs in pulmonary nerve cells has scarcely studied. We investigated the expression of TLRs in pulmonary nerve cells and change of TLRs in bleomycin induced lung fibrosis model. Methods: Male Spraque-Dawley rats were given a single dose of bleomycin (2.5 mg/kg, intratracheally) in pulmonary fibrosis groups and saline in controls. Fibrotic changes in lung were estimated to occur by BAL, histology and SIRCOL collagen assay. Using real-time PCR, we assessed the expression of TLRs (TLR 1-9) in pulmonary neurons of bleomycin induced lung fibrosis rat model in comparson with normal controls. Results: Bleomycin challenge caused pulmonary fibrosis with increase in collagen content of lung tissue and typical histological findings. We showed strong expression of TLR-2, TLR-5 in pulmonary neuron of bleomycin fibrosis rats versus normal rats. Conclusions: The concerted alteration of expression of TLRs in pulmonary neurons can be of relevance for understanding the pathogenesis of lung fibrosis.
( Jeong Eun Song ),( Hye Won Lee ),( Beom Kyung Kim ),( Seung Up Kim ),( Do Young Kim ),( Sang Hoon Ahn ),( Kwang-hyub Han ),( Jun Yong Park ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Long-term suppression of hepatitis B virus (HBV) DNA by antiviralagents is thought to reduce HCC development and improve hepaticfibrosis in chronic hepatitis B. Entecavir (ETV) and tenofovir (TDF)are first-line nucleos(t)ide analogs (NA) for chronic hepatitis B (CHB) due to their high potency and low genetic barrier to resistance.However, it is not known whether there is any difference in reducingthe risk of HCC between the two NAs. The goal of this retrospectivecohort study was to compare the incidence of HCC and assess whetherhepatic fibrosis was improved in HBV related-compensated liver cirrhosis(LC) on these NAs.Methods: We retrospectively analyzed 213 NAs naive HBV-relatedcompensated LC patients who visited our hospital between 2007and 2013 and started entecavir or tenofovir. The primary objectiveof the study is to compare the incidence of HCC in 118 ETV-treatedand 95 TDF-treated patients. The secondary outcome is to observechanges of non-invasive fibrosis indexes (aminotransferase-to-plateletratio index [APRI〕 and FIB-4) through long-term antiviral therapy.Results: The mean duration of antiviral therapy was 3.4 years (ETV4.3 years and TDF 2.4 years). The cumulative probabilities of achievingvirologic response at week 96 were 93.2% and 95.8% in ETV groupand TDF group, respectively (p=0.042). After a median 1.3 years oftreatment, 14 cases of HCC were diagnosed: 7 in the ETV groupand 7 in the TDF group (5.9% vs. 7.4%, p=0.674). In both treatmentgroup, there were significant differences in the reduction of APRIand FIB-4 scores through long-term antiviral therapy.Conclusions: There is no difference in the HCC incidence betweenHBV related-compensated LC patients on ETV and TDF. Long-termantiviral therapy shows improvements in APRI and FIB-4 score.
( Jeong Eun Song ),( Hye Won Lee ),( Beom Kyung Kim ),( Seung Up Kim ),( Do Young Kim ),( Sang Hoon Ahn ),( Kwang-hyub Han ),( Jun Yong Park ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: The impact of superimposed non-alcoholic fatty liver disease (NAFLD) is well known in patients with chronic hepatitis C, however the impact in patients with chronic hepatitis B (CHB) is less distinct. We aimed to investigate the impact of NAFLD on virologic response to tenofovir treatment with chronic hepatitis B patients. Methods: This study was designed as a retrospective cohort study. Consecutive antiviral-naive CHB patients who visited our hospital between December 2012 and December 2013 and started tenofovir were identified from electronic medical record system. Based on controlled attenuated parameter (CAP), patients were divided into groups with hepatic steatosis (CAP score ≥ 260) and without hepatic steatosis (CAP score < 260). The impact of hepatic steatosis on the virologic response to tenofovir at 46 weeks of therapy was evaluated. We also investigated cumulative probabilities of achieving virologic response (VR) in CHB with and without hepatic steatosis using Kaplan-Meier analysis. Results: A total of 95 patients were involved in the study. Twenty eight out of 95 (28.3%) of CHB patinets had hepatic steatosis. The baseline characteristics, including age, sex, AST/ALT level, HBV DNA level and liver cirrhosis are not significantly different in both groups. However, CHB patients with hepatic steatosis had a higher body mass index (p < 0.05). The median duration of follow-up was 130 weeks (48-160 weeks). The VR rates in CHB patients at 46 weeks were 74.2% and 74.1% in CHB patients with and without hepatic steatosis, respectively (p>0.05). The cumulative probabilities of achieving VR were not significantly different in both groups (p>0.05). Conclusions: The presence of hepatic steatosis had no impact on the virologic response to tenofovir treatment.
Seung Su Kim,Soon Ho Cheong,Won Jin Lee,Dong Hwa Jun,Myoung Jin Ko,Kwang Rae Cho,Sang Eun Lee,Young Hwan Kim,Se Hun Lim,Jeong Han Lee,Kun Moo Lee,Young Kyun Choe,Young Jae Kim 대한마취과학회 2010 Korean Journal of Anesthesiology Vol.58 No.1
Thoracic outlet syndrome has neurologic symptoms caused by compression of brachial plexus, blood vessel symptoms are caused by compression of the artery or vein. The authors report a case of sudden decrease in blood pressure of the left arm after turning the patient from supine position to prone position. They confirmed that the patient had thoracic outlet syndrome after performing computed tomography. (Korean J Anesthesiol 2010; 58: 91~94)
High-power Accelerator for Environmental Applications
Seung-Han Kuk,Sung-Myun Kim,Won-Gu Kang,한범수,Nikolai K. Kuksanov,Kwang-Young Jeong 한국물리학회 2011 THE JOURNAL OF THE KOREAN PHYSICAL SOCIETY Vol.59 No.61
A high-power electron accelerator has been developed for environmental applications by EB TECH Co. Ltd. and BINP. This accelerator, which has double extraction windows, can deliver an electron beam with a power up to 400 kW at 1 MeV through 3 irradiators. Titanium foils are used as the window material and are cooled both by water and a blowing air jet. High voltages are generated through the inductions of the coils in the main accelerator body and SF_6 gases are used to protect against electrical discharges. The first such accelerator was installed in 2005 at the Daegu Dyeing Industrial Complex, Korea, for treating industrial wastewater from textile dyeing industries.